Pharmacological effects of carvedilol on T-type calcium current in murine HL-1 cells

Chunyu Deng1, Fang Rao, Shulin Wu

  • 1Medical Research Center of Guangdong General Hospital, Guangzhou, PR China.

Insights

Carvedilol inhibits T-type calcium channels (I(Ca,T)) in atrial cells, impacting calcium transients. This drug affects channel inactivation and recovery, suggesting a new mechanism for its cardiovascular effects.

Area of Science:

  • Cardiovascular Pharmacology
  • Ion Channel Physiology
  • Cardiac Electrophysiology

Background:

  • Carvedilol is a cardiovascular drug used for conditions like atrial fibrillation.
  • T-type calcium channels (I(Ca,T)) are implicated in atrial arrhythmias.
  • The effect of carvedilol on T-type calcium channels was previously unknown.

Purpose of the Study:

  • To investigate the pharmacological effects of carvedilol on T-type calcium current (I(Ca,T)).
  • To determine if carvedilol influences calcium transients in atrial cells.

Main Methods:

  • Whole-cell patch-clamp technique to record I(Ca,T) in murine HL-1 cells.
  • Confocal laser scanning microscopy and Fluo-4/AM to monitor calcium transients.
  • Concentration-dependent analysis and assessment of channel kinetics.

Main Results:

  • Carvedilol inhibited I(Ca,T) concentration-dependently (IC50 = 2.1 microM).
  • Carvedilol shifted inactivation curves negatively and delayed recovery from inactivation.
  • Inhibition of I(Ca,T) and calcium transients was observed, frequency-dependent.

Conclusions:

  • Carvedilol inhibits T-type calcium current in atrial cells.
  • The mechanism involves preferential interaction with the inactivated state of T-type Ca(2+) channels.
  • This action may contribute to carvedilol's therapeutic effects in cardiovascular diseases.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...